Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Nippon Chemiphar Co., Ltd. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 distinct examiners and 5 distinct art units. Examiner assignments are fully distributed, while the art-unit count indicates that at least one examination group handles more than one current matter. Counsel should use portfolio-level coordination without assuming uniform treatment across all applications.
KIFLE, BRUCK is the busiest examiner, with 1 pending matter. The examiner handles one current action. Counsel can compare issues arising within the shared art-unit context, but each response should remain specific to its examiner, claim set, biological subject matter, and evidentiary record.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| SODERQUIST, ARLEN | 1 | 59.7% | +26.2% |
| RAHMANI, NILOOFAR | 1 | 77.6% | -2.9% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.6% |
| HAGHIGHATIAN, MINA | 1 | 46.0% | +39.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18796012 | BIOCHEMICAL REACTION SUBSTRATE AND ANALYZER | SODERQUIST, ARLEN | — |
| 18694663 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | RAHMANI, NILOOFAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18817846 | P2X4 RECEPTOR ANTAGONIST | KIFLE, BRUCK | — |
| 18796012 | BIOCHEMICAL REACTION SUBSTRATE AND ANALYZER | SODERQUIST, ARLEN | — |
| 17615611 | THERAPEUTIC FOR GOUT OR HYPERURICEMIA | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 17057348 | METABOLISM IMPROVING AGENT | HAGHIGHATIAN, MINA | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1797 | 1 |
| 1691 | 1 |
| 1629 | 1 |
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18817846 | P2X4 RECEPTOR ANTAGONIST | KIFLE, BRUCK | 1624 | DP | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18796012 | BIOCHEMICAL REACTION SUBSTRATE AND ANALYZER | SODERQUIST, ARLEN | 1797 | §102§112Other | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18694663 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | RAHMANI, NILOOFAR | 1691 | §102§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 17615611 | THERAPEUTIC FOR GOUT OR HYPERURICEMIA | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §103§112DP | Non-Final OA | — | Pending | Dec 01, 2021 |
| 17057348 | METABOLISM IMPROVING AGENT | HAGHIGHATIAN, MINA | 1616 | §103 | Final Rejection | — | Pending | Nov 20, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNippon Chemiphar Co., Ltd. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Bruck Kifle has the most, with 1 of Nippon Chemiphar Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
